CureVac NV (CVAC) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
CureVac NV stock (CVAC) is currently trading at $4.66. CureVac NV PE ratio is 6.96. CureVac NV PS ratio (Price-to-Sales) is 14.83. Analyst consensus price target for CVAC is $5.41. WallStSmart rates CVAC as Hold.
- CVAC PE ratio analysis and historical PE chart
- CVAC PS ratio (Price-to-Sales) history and trend
- CVAC intrinsic value — DCF, Graham Number, EPV models
- CVAC stock price prediction 2025 2026 2027 2028 2029 2030
- CVAC fair value vs current price
- CVAC insider transactions and insider buying
- Is CVAC undervalued or overvalued?
- CureVac NV financial analysis — revenue, earnings, cash flow
- CVAC Piotroski F-Score and Altman Z-Score
- CVAC analyst price target and Smart Rating
CureVac NV
📊 No data available
Try selecting a different time range
CVAC Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · CureVac NV (CVAC)
CVAC trades at a significant discount to its Graham intrinsic value of $30.28, offering a 85% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
CureVac NV (CVAC) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, operating margin, price/book. Concerns around price/sales and revenue growth. Fundamentals are solid but monitor weak areas for improvement.
CureVac NV (CVAC) Key Strengths (5)
Every $100 of shareholder equity generates $40 in profit
Keeps $573 of every $100 in revenue after operating costs
Keeps $182 of every $100 in revenue as net profit
Trading at 1.03x book value, attractively priced
Strong earnings growth at 24.00% per year
Supporting Valuation Data
CureVac NV (CVAC) Areas to Watch (4)
Revenue declining -89.00%, a shrinking business
Very expensive at 14.8x annual revenue
Very low institutional interest at 10.43%
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
CureVac NV (CVAC) Detailed Analysis Report
Overall Assessment
This company scores 56/100 in our Smart Analysis, earning a C grade. Out of 9 metrics analyzed, 5 register as strengths (avg 9.2/10) while 4 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Operating Margin, Profit Margin. Valuation metrics including Price/Book (1.03) suggest the stock is attractively priced. Profitability is solid with Return on Equity at 40.20%, Operating Margin at 573.00%, Profit Margin at 182.10%. Growth metrics are encouraging with EPS Growth at 24.00%.
The Bear Case
The primary concerns are Revenue Growth, Price/Sales, Institutional Own.. Some valuation metrics including Price/Sales (14.83) suggest expensive pricing. Growth concerns include Revenue Growth at -89.00%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 40.20% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -89.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Operating Margin) and negatives (Revenue Growth, Price/Sales). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CVAC Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CVAC's Price-to-Sales ratio of 14.83x trades at a deep discount to its historical average of 70.39x (38th percentile). The current valuation is 96% below its historical high of 392.38x set in Apr 2021, and 1201% above its historical low of 1.14x in Oct 2024. Over the past 12 months, the PS ratio has expanded from ~1.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for CureVac NV (CVAC) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
CureVac NV faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 71M with 89% decline year-over-year. Profit margins are strong at 182.1%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 40.2% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Profit margin of 182.1% and operating margin of 573.0% demonstrate strong pricing power and operational efficiency.
Revenue contracted 89% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Volatility is elevated with a beta of 1.84, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact CureVac NV.
Bottom Line
CureVac NV faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About CureVac NV(CVAC)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). The company is headquartered in Tbingen, Germany.